Jo-Ann

Jaan Biotherapeutics is a private biotechnology company focused on developing a new class of therapies to treat cardiovascular diseases by activating cardiac regeneration. The company's proprietary technology platform manipulates specific microRNAs to restart the endogenous cardiac muscle regeneration process, which is typically dormant in adult human hearts. Their lead programs target ischemic heart disease (IHD) and hypertrophic cardiomyopathy (HCM), with additional applications in rare diseases like Duchenne muscular dystrophy (DMD). Jaan Biotherapeutics aims to transition its lead candidates into clinical testing by 2027, supported by a robust portfolio of over 30 patents and multiple NIH Small Business grants.